课题基金 / 基金详情

Preclinical Models Core

Preclinical Models Core
临床前模型核心
批准号:
10617220
负责人:
Tatiana Kisseleva
金额:
$26.43万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
未结题
起止时间:
2019-07-01 至 2025-04-30

项目摘要

项目成果

Tatiana Kisseleva的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 圣地亚哥消化疾病研究中心的临床前模型核心将提供 用于临床前研究的胃肠道和肝脏疾病的动物模型,并将有助于表征 以全面和统一的方式前瞻性和回溯性地开展疾病活动。《核心》 源自过去由NIDDK资助的(R24)哥伦比亚大学迷你中心提供的核心服务 加州大学圣地亚哥分校(UCSD)。创建临床前模型核心的方法是基于信息 根据对中心成员需求的调查,UCSD以前的迷你中心的经验,广泛的专业知识 中心成员对消化系统疾病研究的看法,以及几位具有 曾担任其他Silvio O.Conte中心的顾问或领导职务。核心将在以下方面提供资源 兽医科学和技术基础设施,使动物能够得到全面研究。这个 服务将包括就消化系统疾病动物模型的选择和解释提供咨询, 死前成像和死后检查,包括记分的发展和解释 受过比较病理学培训的兽医的系统。因此,核心将是真正的“临床前”,因为它将 使用仪器对疾病进行建模和评估也可用于患者,其另一个优点是 在这些模型中可能进行的受控操作。核心将由两名经验丰富的领导人领导 在将动物模型应用于基础和临床前问题方面有良好的记录:Peter Ernst博士,博士 在管理核心设施方面拥有丰富经验的兽医将担任核心总监并专注于 胃肠道疾病的小鼠模型和活体成像。作为核心联席主任,Tatiana Kisseleva博士 将为她在肝病动物模型方面提供丰富的经验。此外,核心将与 通过以下方式直接补充人类翻译、微生物学和功能基因组学核心 能够在动物模型中将成像结果、生物标记物和临床数据与特定结果联系起来 和人类疾病。因此,临床前模型核心将使中心的研究人员受益,因为它提供 与调查人员的研究和其他核心协调一致的可靠、经济高效的服务 促进和推进与胃肠道和肝脏相关的研究。
英文摘要
Summary The Preclinical Models Core in the San Diego Digestive Diseases Research Center will provide access to animal models of gastrointestinal and liver disease for preclinical studies and will assist in characterizing disease activity prospectively and retrospectively in a comprehensive and uniform manner. The Core emanated out of core services provided by a past NIDDK-funded (R24) Mini-Center at the University of California, San Diego (UCSD). The approach to create the Preclinical Models Core is based on information from surveys of Center member needs, experience with the prior Mini-Center at UCSD, the broad expertise of Center members in digestive diseases research, and the insights of several of the Center members who have served as advisors or in leadership roles for other Silvio O. Conte Centers. The Core will provide resources in veterinary sciences and a technical infrastructure that enables animals to be studied comprehensively. The services will include consultation on the selection and interpretation of animal models of digestive diseases, ante-mortem imaging and post-mortem examination, including the development and interpretation of scoring systems by veterinarians trained in comparative pathology. Thus, the Core will truly be “preclinical” in that it will be modeling and evaluating disease with instrumentation also used in patients with the added advantage of the controlled manipulations that are possible in these models. The Core will be led by two experienced leaders with strong track records in applying animal models to basic and preclinical questions: Dr. Peter Ernst, a PhD veterinarian with extensive experience in managing Core facilities, will be the Core Director and focus on murine models of gastrointestinal disease and in vivo imaging. As the Core Co-Director, Dr. Tatiana Kisseleva will provide her extensive experience with animal models of liver disease. Furthermore, the Core will interact with and directly complement the Human Translational and Microbiomics and Functional Genomics Cores by being able to relate the imaging results, biomarkers and clinical data to specific outcomes in animal models and human disease. Thus, the Preclinical Models Core will benefit the investigators in the Center by providing reliable, cost-effective services that are coordinated with the investigators’ research and other Cores to facilitate and advance research related to the gastrointestinal tract and liver.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of IL-17 signaling in alcohol-induced HCC
The role of IL-17 signaling in alcohol-induced HCC
Novel IL-23 inhibitor for the treatment of alcohol associated liver disease
Novel IL-23 inhibitor for the treatment of alcohol associated liver disease
海外基金